Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 257-036-7
CAS number: 51181-50-1
The estimated amount of Ca-DTPA deposited in
the lung and the Ca-DTPA aerosol size parameters are shown in Table I.
The Ca-DTPA and NaCI doses were calculated from the measured aerosol
concentrations, a minute volume of 0.191/min (estimated for a 320-g rat
from data in refs. 14, 15) and retention by the lung of 30% of the
inhaled aerosol. The latter value is in the 20-30% retention range
quoted by VoIf  and is in agreement with the deposition fraction for
1.4 to 2.5-gm MMAD particles in the human lung  . In rats 100% of
DTPA reaching the deep lung, 15% of that on the nasopharyngeal surfaces,
and 30% of that on the trachea is absorbed  , as is about 5% of the
DTPA swallowed.  . Similar values have been reported for the dog
 . Consequently, one would expect a greater absorbed dose of DTPA
than that represented by the lung deposit alone. In eight preliminary
experiments in¬volving 4 rats per exposure DTPA measured in urine
collected over 24-48 h [20,21], representing > 95% of the absorbed dose
 , averaged 43% (sx = 7.6%) of the calculated inhaled DTPA. This
compares favorably to our as¬sumed 30% deposition in the lung. The
inhalation treatment of humans with Ca-DTPA usually involves a 15 to
30-min exposure to aerosols produced from 1 g of Ca-DTPA in the
nebulizer solution [1-3,22] with doses estimated at 10 -30% of the
aerosol (< 5 mg/kg for a 70 -kg man). Thus,
the doses for rats in Table I are roughly 2-9 times those typically
encountered by man.
Inhalation of calcium trisodium
diethylenetriaminepentaacetate (Ca-DTPA) increases the removal of
plutonium and other transuranics from the body.
Data are required to determine possible
biological effects from inhaled DTPA. Female rats were given a single or
12 daily, 2-4-h, inhalation exposures to aerosols of 10, 20 and 40%
Ca-DTPA and the lungs were examined at 21 and 42 days following the last
exposure. No pulmonary pathology was found from the single inhalation
treatment with Ca-DTPA while only a slight, peripheral, histiocytosis
was observed in the lungs of multiple-treated rats. There was no
significant effect of DTPA treatments on body weight, lung weight,
hematology or serum chemistry values.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again